Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Zakharia, Y. [1 ]
Thomaidou, D. [2 ]
Li, B. [3 ]
Siu, G. [3 ]
Levin, R. [4 ]
Vlahiotis, A. [4 ]
Zanotti, G. [5 ]
机构：
[1] Univ Iowa Hosp & Clin, Holden Comprehens Canc Ctr, Iowa City, IA USA
[2] Pfizer Inc, Global Med Affairs, Pfizer Oncol, Hellas, Greece
[3] Pfizer Inc, Global Prod Dev, Global Biometr & Data Management, New York, NY USA
[4] Pfizer Inc, Real World Evidence Ctr Excellence, New York, NY USA
[5] Pfizer Inc, Hlth Econ & Outcome Res, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111P
引用
收藏
页码：S1423 / S1424
页数：2
相关论文
共 50 条
  • [1] Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordan
    Levin, Rebecca
    Vlahiotis, Anna
    Zanotti, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States
    Zakharia, Yousef
    Vlahiotis, Anna
    Siu, Gordon
    Rao, Dharanija
    Teresi, Rosemary
    Eccleston, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
    Harada, Ken-ichi
    Sato, Ryo
    Bando, Yukari
    Sano, Asuka
    Matsushita, Yuto
    Tamura, Keita
    Terakawa, Tomoaki
    Furukawa, Junya
    Fujimoto, Naohiro
    Fujisawa, Masato
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 772 - 777
  • [4] Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordon
    Levin, Rebecca
    Vlahiotis, Anna
    Rao, Dharanija
    Zanotti, Giovanni
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
    Dong, P.
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Zhou, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1560 - S1561
  • [6] Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    Dong, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1559 - S1560
  • [7] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [8] Pembrolizumab plus axitinib beyond first-line therapy for mRCC
    Thomas, Tim
    NATURE REVIEWS UROLOGY, 2023, 20 (3) : 131 - 131
  • [9] Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
    Kondo, Tsunenori
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 777 - 778
  • [10] Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.
    Allison, Jennifer
    Charnley, Natalie
    Stevenson, Robert
    Waddell, Tom
    Pillai, Manon Rhys
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345